Related coverage linked through entity extraction aliases.
May 09, 2026
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
May 02, 2026
Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.
Apr 28, 2026
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Apr 21, 2026
Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.
Apr 18, 2026
Teva said the FDA accepted its New Drug Application for long-acting olanzapine for schizophrenia, with a decision expected later this year. The company also reported Austedo sales of $2.26 billion in 2025 and plans six biosimilar launches in 2026 and 2027.
Apr 13, 2026
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.
Mar 26, 2026
The FDA approved milsaperidone for bipolar I disorder and schizophrenia, while COMP360 psilocybin met its primary endpoint in a second phase 3 trial for treatment-resistant depression. Phase 2a data showed intravenous DMT (SPL026) significantly reduced depressive symptoms in major depressive disorder patients.
Mar 18, 2026
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Mar 12, 2026
Researchers identify speech latency as a biomarker to enrich schizophrenia clinical trials, while a separate study finds clozapine more effective than alternatives for patients who fail initial antipsychotic treatment.
Mar 05, 2026
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
Mar 03, 2026
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Mar 03, 2026
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Mar 01, 2026
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Feb 25, 2026
The FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in adults, and accepted Vanda's BLA filing for imsidolimab to treat Generalized Pustular Psoriasis with a target action date of December 12, 2026.
Feb 21, 2026
The FDA has accepted Teva Pharmaceuticals' New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine injection for treating schizophrenia in adults, based on Phase 3 trial data showing efficacy consistent with existing formulations without requiring post-injection monitoring.
Feb 20, 2026
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone), an atypical antipsychotic for schizophrenia and manic or mixed episodes in bipolar I disorder. The drug will be available by the third quarter of 2026.
Feb 21, 2026
The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' Bysanti for treating schizophrenia and acute bipolar I disorder. The company expects to launch the drug in the third quarter of 2026.
Feb 22, 2026
Bristol Myers Squibb faces a steep patent cliff with key drugs losing protection between 2027-2029, but newer products like Cobenfy show promise. The stock trades at less than 10 times earnings with a 4.2% dividend yield.
Feb 20, 2026
The FDA has accepted Teva Pharmaceutical's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine extended-release injectable suspension for treating schizophrenia in adults, supported by Phase 3 SOLARIS trial data.
Feb 21, 2026
The FDA has accepted Teva and Medincell's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine formulation for schizophrenia treatment that showed no need for post-injection monitoring in Phase 3 trials.
